Flavone acetic acid analogs and methods of use thereof

Abstract

Compounds are described having a structure according to Formula I or Formula II: wherein: X is selected from the group consisting of O, NH, and S; Y is selected from the group consisting of O and S; m is from 1 to 3; n is from 1 to 5; R 1 and R 3 are each independently selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, halo, amino, aminoalkyl, nitro, heteroaryl, —OC(═O)R 6 , —O(C═O)OR 6 ; and —O(C═O)N(R 6 ) 2 ; and R 2 is side chain such as an acetic acid side chain, where p is O to 4, R 5 is hydroxy, alkoxy or amino, and R 6 is H or lower alkyl, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer.

1 . A compound having a structure according to Formula II:  
       
         
           
           
               
               
           
         
       
       wherein: 
 X is NH;  
 Y is selected from the group consisting of O and S;  
 m is from 1 to 3;  
 n is from 1 to 5;  
 R 1  and R 3  are each independently selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, halo, amino, aminoalkyl, nitro, heteroaryl, —OC(═O)R 6 , —O(C═O)OR 6 ; and —O(C═O)N(R 6 ) 2 ;  
 R 2  is selected from the group consisting of:  
                     
 where p is O to 4, R 5  is hydroxy, alkoxy or amino, and R 6  is H or lower alkyl;  
 or a pharmaceutically acceptable salt thereof.  
 
     
     
         2 . (canceled)  
     
     
         3 . A compound according to  claim 1  having a structure according to Formula I, and wherein R 2  is bonded at the 8 position.  
     
     
         4 - 7 . (canceled)  
     
     
         8 . A compound according to  claim 1  wherein Y is O.  
     
     
         9 . A compound according to  claim 1  wherein Y is S.  
     
     
         10 . A compound according to  claim 1  wherein R 1  is H or alkyl.  
     
     
         11 . A compound according to  claim 1  wherein R 3  is H or alkyl.  
     
     
         12 . A compound according to  claim 1  wherein R 2  is selected from the group consisting of:  
       
         
           
           
               
               
           
         
       
     
     
         13 . A pharmaceutical formulation comprising a compound according to  claim 1  in a pharmaceutically acceptable carrier.  
     
     
         14 . The pharmaceutical formulation according to  claim 13 , wherein said carrier is an aqueous carrier.  
     
     
         15 . A method of treating a cancer, comprising administering to a subject in need thereof a treatment effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof.  
     
     
         16 . The method according to  claim 15 , wherein said cancer is selected from the group consisting of skin cancer, lung cancer, Kaposi's sarcoma, testicular cancer, lymphoma, leukemia, esophageal cancer, stomach cancer, colon cancer, breast cancer, endometrial cancer, ovarian cancer, central nervous system cancer, liver cancer and prostate cancer.  
     
     
         17 . The method according to  claim 15 , wherein said cancer is prostate cancer.  
     
     
         18 . The method according to  claim 15 , wherein said cancer is colon cancer.  
     
     
         19 . The method according to  claim 15 , wherein said cancer is lung cancer.  
     
     
         20 . The method according to  claim 15 , wherein said cancer is breast cancer.